{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T22:40:51Z","timestamp":1648939251867},"reference-count":9,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/naika.102.1971","type":"journal-article","created":{"date-parts":[[2014,8,9]],"date-time":"2014-08-09T23:06:45Z","timestamp":1407625605000},"page":"1971-1977","source":"Crossref","is-referenced-by-count":0,"title":["9. Therapeutic Progress in Multiple Sclerosis and Neuromyelitis Optica"],"prefix":"10.2169","volume":"102","author":[{"given":"Masami","family":"Tanaka","sequence":"first","affiliation":[{"name":"Multiple Sclerosis Center, NHO Utano National Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kanazawa Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tanaka M: Topics of MS research presented at the 65<sup>th<\/sup> American Academy of Neurology Annual Meeting held at San Diego in 2013. Clin Exp Neuroimmunol..","DOI":"10.1111\/cen3.12022"},{"key":"2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kieseier BC, et al: A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nat Rev Neurol 7: 255-262, 2011.","DOI":"10.1038\/nrneurol.2011.41"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Coles AJ, et al: Alemtuzumab versus interferon \u03b2-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10: 338-348, 2011.","DOI":"10.1016\/S1474-4422(11)70020-5"},{"key":"5","unstructured":"5) Tanaka M, et al: Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia. Mult Scler. in press."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gorelik L, et al: Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295-303, 2010.","DOI":"10.1002\/ana.22128"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Jarius S, Wildemann B: AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6: 383-392, 2010.","DOI":"10.1038\/nrneurol.2010.72"},{"key":"8"},{"key":"9","unstructured":"9) Pittock SJ, et al: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013 Apr 25. pii: S1474-4422 (13) 70076-0. doi: 10.1016\/S1474-4422 (13) 70076-0."}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/8\/102_1971\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T16:58:19Z","timestamp":1621443499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/102\/8\/102_1971\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.102.1971","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}